It has been reported that EZH2 can be used as a catalytic subunit of PRC2, the complex that participates in the transcriptional inhibition of multiple target genes, including the inactivation of more than 200 tumor suppressor genes [12]. The gene discussed is EZH2; the disease is neoplasm.